• Explore /
  • Poster
  • / Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.

Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.

Abstract Poster

Authors

Judy Wang

Judy S. Wang

Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL

Judy S. Wang , David Sommerhalder , Manish Sharma , William Jeffery Edenfield , Kartik Sehgal , Do-Youn Oh , Yixing Jiang , Joel Michalski , Jeeyun Lee , Hans J. Hammers , Li-Yuan Bai , Chih-Hung Hsu , Brenda A. P. Dampier , Kefei Zhou , Lisa K. Blum , Joanne Sloan Lancaster , Dhiraj J. Abhyankar , Hsiao D. Lieu , Vladimir Hanes , Aung Naing

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04913337

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2582)

DOI

10.1200/JCO.2024.42.16_suppl.2582

Abstract #

2582

Poster Bd #

61

Abstract Disclosures

Similar Posters

First Author: Meredith McKean

First Author: Susanna Varkey Ulahannan

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.

Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.

First Author: Daneng Li

First Author: Yelena Y. Janjigian